CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED) (USD $)	9 Months Ended
	Jul. 31, 2014	Jul. 31, 2013
Reconciliation of net loss to net cash used in operating activities:
Net loss	$ (6,452,870)	$ (7,153,332)
Stock option compensation to employees	1,562,350	2,118,424
Stock option compensation to consultants	784,237	574,374
Common stock issued to consultants	40,748	168,475
Common stock issued to pay interest on convertible debentures	61,778	69,939
Amortization of patents	233,129	0
Amortized interest on patent acquisition obligations to interest expense	286,002
Amortization of convertible debenture discount to interest expense	575,210	893,149
Loss on extinguishment of debt	482,915	343,517
Change in value of derivative liability	1,460,704	(315,189)
Common stock issued to acquire patent license	62,000	42,000
Other	(553)	35,490
Change in operating assets and liabilities:
Accounts receivable	41,667
Prepaid expenses and other current assets	60,066	8,574
Accounts payable and accrued expenses	28,101	572,180
Royalties and contingent legal fees payable	(55,343)
Deferred revenue	(1,187,320)
Net cash used in operating activities	(2,017,179)	(2,642,399)
Cash flows from investing activities:
Disbursements to acquire short-term investments in certificates of deposit	(3,700,000)
Proceeds from sales of short-term investments in certificates of deposit	1,150,000	500,000
Other	(3,798)	(676)
Net cash (used in) provided by investing activities	(2,553,798)	499,324
Cash flows from financing activities:
Proceeds from issuance of convertible debentures	3,500,000	1,765,000
Proceeds from sale of common stock	3,673,135	589,865
Payments to redeem convertible debentures	(200,000)
Proceeds from exercise of warrants to purchase common stock	300,009	380,800
Proceeds from exercise of employee stock options	51,225	25,610
Net cash provided by financing activities	7,324,369	2,785,413
Net increase in cash and cash equivalents	2,753,392	642,338
Cash and cash equivalents at beginning of year	898,172	339,693
Cash and cash equivalents at end of period	3,651,564	982,031
Supplemental disclosure of non-cash investing and financing activities:
Non-cash patent acquisition	3,036,111
Common stock to acquire patent license	247,600	42,000
Common stock issued upon conversion of convertible debentures	2,735,349	1,353,364
Fair value of debenture embedded conversion feature at date of issuance	1,570,000	1,180,000
Relative fair value of warrants issued with convertible debentures	513,112	214,819
ZQX Advisors LLC [Member]
Cash flows from financing activities:
Proceeds from sale of common stock		$ 24,138